<abstract xmlns="http://www.w3.org/1999/xhtml"><sec><h3>Background</h3><p>Epidermal growth factor receptor (<italic>EGFR</italic>) sequence variants in patients from Myanmar have not yet been reported.</p></sec><sec><h3>Objectives</h3><p>To describe the molecular epidemiology of <italic>EGFR</italic> variants in patients from Myanmar with lung adenocarcinoma.</p></sec><sec><h3>Methods</h3><p>Histological diagnosis and categorization of biopsies collected from 66 patients (28–78 years) with lung cancer was conducted using a panel of antibodies including those to: TTF1, P40, synaptophysin, CK7, and napsin-A. Samples from patients with confirmed adenocarcinoma were tested for <italic>EGFR</italic> variants using a cobas EGFR Mutation Test kit and cobas z 480 System (Roche). We conducted a univariate analysis of categorical factors using a χ<sup>2</sup> or Fisher exact test.</p></sec><sec><h3>Results</h3><p>Histological types were adenocarcinoma (61%, 40/66), squamous cell carcinoma (24%, 16/66), neuroendocrine carcinoma (9%, 6/66), undifferentiated carcinoma (2%, 1/66), adenosquamous carcinoma (2%, 1/66), small cell anaplastic carcinoma (2%, 1/66), and pleomorphic sarcoma (2%, 1/66). <italic>EGFR</italic> variants were detected in 15 of 40 (38%) cases of adenocarcinoma. Among them, 6 patients (40%) had an exon 19 deletion, another 6 (40%) had exon 21 substitutions, 1 (7%) had exon 20 insertion S768I, and 2 (13%) had compound variations (1 of exon 21 L858R and exon 18 G719X, and 1 of exon 20 S768I and exon 18 G719X). Although limited by small sample size, no significant association was found between the variants and factors including family cancer history, age group, sex, ethnicity, or occupation. However, there was a strong significant association between never-smokers and <italic>EGFR</italic> variants (<italic>P</italic> = 0.008).</p></sec><sec><h3>Conclusion</h3><p>Knowledge of <italic>EGFR</italic> variants in patients from Myanmar is encouraging for their effective cancer treatment.</p></sec></abstract>

BackgroundEpidermal growth factor receptor (EGFR) sequence variants in patients from Myanmar have not yet been reported.ObjectivesTo describe the molecular epidemiology of EGFR variants in patients from Myanmar with lung adenocarcinoma.MethodsHistological diagnosis and categorization of biopsies collected from 66 patients (28–78 years) with lung cancer was conducted using a panel of antibodies including those to: TTF1, P40, synaptophysin, CK7, and napsin-A. Samples from patients with confirmed adenocarcinoma were tested for EGFR variants using a cobas EGFR Mutation Test kit and cobas z 480 System (Roche). We conducted a univariate analysis of categorical factors using a χ2 or Fisher exact test.ResultsHistological types were adenocarcinoma (61%, 40/66), squamous cell carcinoma (24%, 16/66), neuroendocrine carcinoma (9%, 6/66), undifferentiated carcinoma (2%, 1/66), adenosquamous carcinoma (2%, 1/66), small cell anaplastic carcinoma (2%, 1/66), and pleomorphic sarcoma (2%, 1/66). EGFR variants were detected in 15 of 40 (38%) cases of adenocarcinoma. Among them, 6 patients (40%) had an exon 19 deletion, another 6 (40%) had exon 21 substitutions, 1 (7%) had exon 20 insertion S768I, and 2 (13%) had compound variations (1 of exon 21 L858R and exon 18 G719X, and 1 of exon 20 S768I and exon 18 G719X). Although limited by small sample size, no significant association was found between the variants and factors including family cancer history, age group, sex, ethnicity, or occupation. However, there was a strong significant association between never-smokers and EGFR variants (P = 0.008).ConclusionKnowledge of EGFR variants in patients from Myanmar is encouraging for their effective cancer treatment.

Epidermal growth factor receptor variants in patients from Myanmar with lung adenocarcinoma

prof.khinesanyin@innovativediagnosticsmyanmar.com

Asian Biomedicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

BackgroundEpidermal growth factor receptor (EGFR) sequence variants in patients from Myanmar have not yet been reported.ObjectivesTo describe the molecular...

Epidermal growth factor receptor variants in patients from Myanmar with lung adenocarcinoma

Article Category: Brief communication (original)

Pubblicato online: 04 ago 2020

Pagine: 75 - 81

DOI: https://doi.org/10.1515/abm-2020-0011

Parole chiave
adenocarcinoma of lung, EGFR protein, human, ErbB receptors, Myanmar, carcinoma, non-small-cell lung

© 2020 Khine San Yin et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Epidermal growth factor receptor variants in patients from Myanmar with lung adenocarcinoma

Article Category: Brief communication (original)

Pubblicato online: 04 ago 2020

Pagine: 75 - 81

DOI: https://doi.org/10.1515/abm-2020-0011

Parole chiaveadenocarcinoma of lung, EGFR protein, human, ErbB receptors, Myanmar, carcinoma, non-small-cell lung

© 2020 Khine San Yin et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Parole chiave
adenocarcinoma of lung, EGFR protein, human, ErbB receptors, Myanmar, carcinoma, non-small-cell lung